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RESEARCH ARTICLE
Assessment of prolactin associated platelet activation in ischemic stroke
İskemik inmede prolaktin ilişkili platelet aktivasyonunun değerlendirilmesi
Ayşegül Akagündüz Ege, Şule Bilen, Fikri Ak
Neurology Clinic of Ankara Numune Education and Research Hospital, Ankara, Turkey
ÖZET
Amaç: İskemik inme ile prolaktin seviyeleri, prolaktin iliş-
kili platelet aktivasyonu arasında ilişki olup olmadığı ve 
iskemik inme etyolojisinde rolleri olup olmadığının araştı-
rılmasını amaçladık.
Gereç ve yöntem: Çalışmaya akut iskemik inme tanısı 
almış olan 57 hasta ile iskemik vasküler hastalık hikayesi 
olmayan, yaş ve cinsiyet uyumlu 43 kontrol olgusu dahil 
edildi. Hastaların 12 saat açlığı takiben değerlendirilen 
prolaktin seviyeleri, platelet sayısı ve platelet aktivasyo-
nunun bir göstergesi olan ortalama platelet hacmi (OPH) 
kontrol grubunun ölçümleri ile karşılaştırıldı.
Bulgular: Hastaların prolaktin seviyeleri anlamlı şekilde 
yüksekti. Prolaktin seviyeleri ile erken OPH ölçümleri ara-
sında bir ilişki bulunmadı. OPH açısından bir fark yok iken 
platelet sayısı hasta grubunda anlamlı şekilde yüksekti.
Sonuç: Bu çalışmada prolaktinin ortalama platelet hacmi 
üzerinde bir etkisinin varlığı veya erken iskemik inme ve 
OPH arasında bir ilişki gösterilememiştir. Ancak iskemik 
inmeli hastalarda, erken dönemde yüksek prolaktin se-
viyesi ve yüksek platelet sayısı varlığı iskemik olayların 
etyolojisinde anlamlı olabilir. Bunun yanı sıra iskemik in-
menin erken döneminde yüksek prolaktin seviyesi bulun-
ması iskemik inmenin patogenezinde prolaktin artışının 
rolü olabileceğini düşündürebilir.
Anahtar kelimeler:  İskemik  inme,  prolaktin,  ortalama 
platelet hacmi, platelet sayısı
ABSTRACT
Objectives: We aimed to investigate whether there were 
any relations between prolactin levels, prolactin associ-
ated platelet activation and ischemic stroke, and whether 
they had role in etiology of ischemic stroke.
Materials and methods:  Totally  57  patients  with  the 
diagnosis of acute ischemic stroke and 43 age and sex 
matched controls with no history of ischemic vascular dis-
eases were included in the study. Prolactin levels, mean 
platelet volume (MPV) a marker of platelet activation, and 
platelet count, of the patients, after 12 hours of fasting, 
compared with the measurements of control group.
Results: Patients had significantly higher prolactin levels. 
A correlation between prolactin levels and early measure-
ments of MPV was not detected. While there was no dif-
ference in terms of MPV, the platelet count was signifi-
cantly higher in the patient group.
Conclusions: In the present study, the existence of an 
effect of prolactin on the mean platelet volume, or a re-
lationship between early ischemic stroke and MPV could 
not be shown. However, in ischemic stroke patients, in 
early phase, presence of higher levels of prolactin and 
platelet count may be meaningful in etiology of ischemic 
events. Besides, presence of higher prolactin levels in 
early phase of ischemic stroke may lead to consider the 
potential  role  of  prolactin  elevation  in  ischemic  stroke 
pathogenesis. J Clin Exp Invest 2012; 3(1): 1-6
Key words: Ischemic stroke, prolactin, mean platelet vol-
ume, platelet count
INTRODUCTION
Cerebrovascular  disease  is  one  of  the  most  fre-
quently occurring and significant neurological disor-
ders among the adult population.
Today, it is a widely accepted view that the risk 
of ischemic stroke is increased by a number of fac-
tors that can be classified as modifiable and non-
modifiable. Non-modifiable risk factors for stroke in-
clude advanced age, male gender, ethnic group and 
a family history of stroke. Modifiable risk factors are 
divided into two separate groups, which in turn are 
categorized as lifestyle dependent and non-lifestyle 
dependent  risks.  Lifestyle-dependent  risk  factors 
include  smoking  and  illicit  drug  use.  Risk  factors 
independent of lifestyle include low socioeconomic 
status,  arterial  hypertension,  dyslipidemia,  heart 
disease and asymptomatic carotid artery disease.1 
In addition to these factors, several potential risk 
factors have also been identified in recent years. A. A. Ege et al. Platelet activation in ischemic stroke 2
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The identification of new risk factors contributes to a 
better understanding of the pathophysiology of the 
disease  and  possible  treatment  strategies.  Plate-
let activation and aggregation have been shown to 
play an important role in the pathophysiology of ath-
erosclerosis and thrombosis in acute and chronic 
arterial diseases.2,3 Prolactin is known to contribute 
to  this  process  by  increasing  platelet  activation. 
Mean platelet volume is an indicator of platelet acti-
vation. Larger-sized platelets are more reactive and 
many  phases  of  this  activation  are  mediated  via 
ADP and P-selectin expression on which prolactin 
has a direct effect.4 These pathophysiological pro-
cesses are thought to be also relevant in ischemic 
stroke.5-10 In addition, prolactin has been described 
as causing increased in vivo and in vitro platelet ag-
gregation.11 and increased platelet aggregation as 
arising with the effect of prolactin;12 and these pro-
cesses are thought to contribute to the pathophysi-
ology of stroke.
In this study, we aimed to investigate the re-
lationship of prolactin levels and platelet activation 
associated  with  prolactin  to  the  risk  of  ischemic 
stroke, and whether they have a role in its etiology.
MATERIALS AND METHODS
Patients  monitored  following  diagnosis  of  acute 
ischemic  cerebrovascular  event  at  the  Neurology 
Clinics of Ankara Numune Education and Research 
Hospital between June 2008 and September 2009 
were  randomized  and  enrolled  in  the  study.  The 
control  group  included  age  and  gender  matched 
individuals who met the defined inclusion criteria. 
Patients’ histories, neurological examinations, and 
brain images (computed tomography and/or mag-
netic resonance imaging) were used for the diagno-
sis of ischemic cerebrovascular events. Presence of 
peripheral arterial disease, coronary artery disease, 
chronic diseases (hypertension, diabetes mellitus, 
chronic renal failure, endocrine / metabolic disor-
ders, malignancies), previous surgical procedures 
and  head  trauma,  alcohol  consumption  and  sub-
stance abuse were asked.
Alcohol consumption, substance users, those 
who had undergone intracranial surgery, epileptics, 
those with intracranial mass, metabolic and endo-
crine diseases, chronic renal failure, hepatic failure, 
malignancies, autoimmune and collagen tissue dis-
eases and those using drugs that alter prolactin me-
tabolism  (anti-psychotics,  various  hormone  treat-
ments) were excluded from the study. Also exclud-
ed were individuals with abnormal platelet counts 
and/or platelet dysfunction, proliferative bone mar-
row disease and hematological conditions leading 
to bone marrow suppression, those using various 
drugs that have indirect effects on bone marrow, 
and those with chronic diseases.
Subjects selected for the control group were 
people with no history of ischemic cerebrovascular 
accident,  myocardial  infarction  and  peripheral  ar-
tery disease. Individuals with prolactin metabolism 
disorders and bone marrow dysfunction were also 
excluded from the control group.
There were 57 subjects (29 females, 28 males) 
in the patient group and 43 subjects (23 female and 
20 male) in the control group.
Blood samples were taken from all participating 
subjects (from the patient group within the first day 
of hospital admission) after 12 hours of fasting for 
analysis of biochemical parameters (blood glucose, 
liver function tests, BUN, creatinine, electrolytes, al-
bumin, globulin), lipid panel (LDL cholesterol, HDL 
cholesterol , VLDL cholesterol, total cholesterol and 
triglyceride levels), thyroid function tests (free T3, 
free T4, TSH), complete blood count, erythrocyte 
sedimentation  rate  (ESR)  and  C-reactive  protein 
(CRP).  Neurological  examinations  of  the  patient 
group were evaluated on day 1 and day 10, using 
the  modified  Rankin  Scale.13  Electrocardiograms 
(ECG) and carotid and vertebral artery doppler ul-
trasound (US) scans were performed on all individ-
uals in the patient group. Prolactin levels after 12 
hours of fasting were determined in both groups (in 
patients in the first day of admission).
Prolactin  levels  were  determined  using  the 
Chemiluminescent  Microparticle  Immunoassay 
(CMIA) method of the Beckman Coulter DXI Ana-
lyzer system. Platelet count and mean platelet vol-
ume were determined on a Coulter Gen S complete 
blood count device.
Statistical analysis
SPSS for Windows software version 15.0 was used 
in the statistical analysis. Quantitative parameters 
were examined in terms of mean, standard devia-
tion and median. Qualitative parameters were dem-
onstrated  in  terms  of  numbers  and  percentages. 
The differences in quantitative parameters between 
the two groups were examined using the t-test or 
Mann Whitney test, and the Kruskal-Wallis test was 
used to identify any differences between the three 
groups analyzed. The Chi-square test was used to 
identify any significant differences in terms of gen-
der  distribution  between  groups. The  relationship 
between quantitative parameters was shown with 
the Spearman’s correlation coefficient. The signifi-
cance level was determined as p <0.05.A. A. Ege et al. Platelet activation in ischemic stroke 3
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RESULTS
A total of 100 individuals were included in the study. 
The patient and control groups consisted of 57 and 
43 individuals respectively. There was no significant 
statistical difference between the mean ages of the 
patient (74.8 ± 8.0) and control (71.6 ± 6.9) groups 
(p = 0.214). There were 29 females (50.9%) and 28 
males (49.1%) in the patient group, and 23 females 
(53.5%) and 20 males (46.5%) in the control group. 
The gender distribution of subjects in the patient 
and control groups did not differ significantly (p = 
0.955).
The mean prolactin level was 10.4 mg / dl (15.3 
± 15.9) and 6.6 mg / dl (7.7 ± 3.8) respectively in the 
patient and control groups. In the patient group, the 
mean prolactin level was significantly higher com-
pared to the control group (p = 0.001). However, a 
comparison of CRP levels between the patient and 
control groups revealed the average value in the 
patient group to be significantly higher (10.5 ± 26.2 
mg/dl, mean = 3.0 mg/dl, 0.7 ± 0.5 mg/dl, mean = 
0.5 mg/dl respectively) (p<0.001) (Figure 1). Within 
the  patient  group  CRP  levels  showed  a  positive 
correlation with prolactin levels (SCC: 0.308, p = 
0.002). Platelet count measured in the patient group 
(279,596.5 ± 101,065.9 / ml) was higher than the 
control group’s platelet count (243651.2 ± 65638.6 
/ ml), and it was statistically significant (p = 0.034). 
Table  1  indicates  significant  differences  between 
the two groups.
Table 1. Prolactin levels, platelet counts and C-reactive protein levels of patients and controls
Patients (n=57) Controls (n=43) P
Prolactin levels (mg/dl) 15.3±15.9 (Median=10.4) 7.7±3.8 (Median=6.6) 0.001
Platelet count, (/µl) 279.596±101.065 243.651±656.38l 0.034
C-reactive protein (mg/dl) 10.5±26.2 (Median=3.0) 0.7±0.5 (Median=0.5) <0.001
Figure 1. Comparison of prolactin and C-reactive protein 
(CRP) levels of patient and control group
The patient and control groups did not differ 
significantly in terms of MPV (P = 0.699). MPV val-
ues of the patient and control groups were 8.2 ± 1.0 
fl and 8.1 ± 1.0 fl respectively. In the patient group, 
mean  platelet  volume  (SCC:  -0.118,  p  =  0.224), 
platelet count (SCC: 0.063, p = 0.531) and ESR 
(SCC: 0.109, p = 0.368) did not show a significant 
correlation with prolactin levels.
When the relationship between prolactin levels 
and carotid artery pathology was analyzed in the pa-
tient group, we found that there was no significant 
relationship between prolactin levels and those of 
isolated intima-media thickness (n = 5, 19.5 ± 24.4, 
mean = 8), those with non-stenotic plaques (n = 28, 
18.2 ± 19.2, mean = 11.7) and those with stenotic 
plaques (n = 23, 11.3 ± 7.1, mean = 9.5).
In the patient group, there was no significant 
correlation between prolactin levels and the pres-
ence of hypertension (n = 47, 16.0 ± 17.2, mean 
= 10.4, p = 0.690), diabetes mellitus (n = 18, 14.1 
± 14.7, mean: 8.9, p = 0.542), atrial fibrillation (n = 
14, 12.8 ± 9.2, mean: 11, p = 0.831) and coronary 
artery disease (n = 26, 13.8 ± 12.6, mean: 10.3, p 
= 0.816).
No significant correlation was observed in the 
baseline and end-of-study modified Rankin scores 
of the patient group when compared with prolactin 
levels (p = 0.371), mean platelet volume (p = 0.802), 
platelet count (0382), and CRP levels (p = 0.903).
DISCUSSION
Ischemic cerebrovascular disease is a health prob-
lem of growing significance given the aging popula-
tion. In addition to well-known risk factors for stroke, 
many  potential  risk  factors  have  been  defined  in 
recent years, and some of these have begun to be 
used  for  screening  purposes.  Today,  clinical  and A. A. Ege et al. Platelet activation in ischemic stroke 4
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laboratory  data  are  available  which  suggest  that 
elevated prolactin levels may be related to the dis-
ease  in  some  measure.  In  our  study,  the  patient 
group had significantly higher prolactin levels com-
pared with healthy controls. These findings suggest 
that prolactin contributes to the pathophysiology of 
ischemic cerebrovascular event. Prolactin contrib-
utes to this process by increasing platelet activa-
tion. Wallaschofski et al demonstrated the in vivo 
and in vitro dose-dependent expression of CD62p 
with prolactin in patients undergoing cerebrovascu-
lar ischemic event, and increased prolactin levels 
were shown in the blood of patients with ischemic 
stroke and transient ischemic attack.14 The same 
investigator  group  also  noted  the  higher  rates  of 
venous thromboembolism in patients with prolacti-
noma.15 The authors attributed these results to in-
creased platelet activation by prolactin via ADP.11,12 
Similarly, Raaz et al claimed that prolactin increases 
ADP  stimulated  P-selectin  expression  in  patients 
with acute coronary syndrome.14
Our  findings  are  consistent  with  the  current 
literature. However, Schwarz et al attribute these 
findings  to  hypothalamic-pituitary-adrenocortical 
axis disturbances.16 Serum prolactin levels are also 
known to increase secondarily to psychogenic and 
physical stress.17 Despite an absent or low-level en-
dogenous stress response in central nervous sys-
tem lesions, they suggest that increasing levels of 
prolactin in these patients are due to impairments 
caused by lesions of the dopaminergic pathways.16 
However,  it  is  debatable  whether  this  hypothesis 
is  applicable  to  all  ischemic  patients  since  the 
Schwarz et al study includes only large space-oc-
cupying ischemic stroke patients. In our study, isch-
emic stroke patients were randomized regardless of 
the infarct size and increased intracranial pressure, 
providing the opportunity to monitor stroke patho-
physiology more directly. We found that there was a 
significant correlation between CRP levels and pro-
lactin elevation, but that CRP levels were unrelated 
to the modified Rankin Scale. In this case, one may 
speculate that the prolactin levels we found may re-
flect an earlier pro-inflammatory process rather than 
the severity of the existing disease. However, more 
studies are needed to clarify whether increased pro-
lactin levels are a primary or secondary phenome-
non. Although the endogenous stress response was 
not triggered sufficiently to raise levels of prolactin 
in central nervous system lesions, there are pro-
spective clinical trials available in literature to reveal 
this relationship.
Prolactin is known to contribute to the process 
by increasing platelet activation. We made use of 
mean  platelet  volume  measurements  to  assess 
this activation. Mean platelet volume is an indica-
tor of platelet activation. Larger-sized platelets are 
more reactive and many phases of this activation 
are mediated via ADP and P-selectin expression on 
which prolactin has a direct effect. In our study, we 
did not detect a significant difference in MPV be-
tween the patient and control groups. When evalu-
ated as a whole in literature, studies investigating 
the association between the risk and and prognostic 
impact of MPV measurements in patients with isch-
emic stroke currently show conflicting data. The first 
question is whether MPV elevation emerges before 
or after the disease, and the second is whether per-
sistent  MPV  elevation  has  a  positive  relationship 
with subsequent vascular events. In a large series 
of 3134 patients with a history of cerebrovascular 
disease, Bath and colleagues concluded that there 
is a positive relationship between high platelet vol-
ume and the risk of ischemic stroke.4
Greisenegger et al noted that higher MPV val-
ues lead to an up to twofold increase in the risk of 
stroke,  particularly  in  the  group  with  higher  MPV 
values.18 A similar clinical trial has demonstrated a 
positive  correlation  between  poor  prognosis  after 
three months and elevated MPV.19 Contrary to these 
results, O’ Malley et al suggested that there is no 
relationship between platelet behavior and progno-
sis after six months.20 In the light of current labora-
tory research data, it is concluded today that MPV 
is associated with production phases in the bone 
marrow and that a variety of cytokines play a role 
in this process, but the same result has not always 
been supported by clinical studies. An increase in 
MPV  and  decrease  in  platelet  counts  have  been 
reported  after  myocardial  infarction,21  and  similar 
trends in platelet ischemic stroke may also apply. 
It  is  suggested  that  MPV  increases  reactively  as 
platelet count decreases. One theory that attempts 
to explain increased MPV is the retention of plate-
lets in the infarct areas and volume changes occur-
ring subsequently.21,22 A similar study shows that in 
cerebral  ischemic  stroke  the  number  of  platelets 
decreased and MPV increased during the 48 hours 
following cerebral infarction.22 This occurrence may 
be related to the emergence of young platelets with 
high MPV in peripheral circulation as a response to 
the decrease in numbers caused by the retention 
of platelets in the infarct area. Elevated MPV may 
persist for one month after the acute event. Another 
study shows decreases in both platelet number and 
MPV following cerebral thrombosis, and suggests 
by way of explanation that the selective loss of large 
and active platelets in the infarct regions during the 
pathological  process  played  an  influential  role  in A. A. Ege et al. Platelet activation in ischemic stroke 5
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the results.9 Many investigators attribute the reason 
for these contradictory results to low patient num-
bers and the designation of different criteria for the 
results. Our results reflect MPV values measured 
within the first 12 hours after ischemic stroke. Our 
results indicate that there was no increase in platelet 
volume prior to the thrombotic process. Since serial 
MPV measurements were not taken in our study, we 
cannot form an opinion as to whether there was a 
falling or rising trend. However, MPV measurements 
showed  no  significant  difference  when  prolactin 
levels were elevated, and this may be due to the 
fact that platelets are able to demonstrate different 
forms of activation. For example, some researchers 
have identified the presence of an isolated enzy-
matic activation, and indeed shown that high rates 
of ATP activity can be found even at stages when 
aggregation is not at adequate levels.8,9 Neverthe-
less, it is arguable to what extent this contributes to 
the pathophysiology of thrombosis. Another expla-
nation for our results may be a negative relationship 
between platelet count and mean platelet volume. 
In blood samples taken within the first 12 hours, the 
number of platelets in the patient group was signifi-
cantly higher compared with controls, which may 
explain low MPV values (MPV decreases as platelet 
count increases). Nevertheless, the fact that platelet 
numbers were significantly higher than in controls 
suggests a platelet-derived predisposition in stroke 
patients. An alternative point of view is that tissue 
ischemia and oxidative stress are known to trigger 
platelet activation,23 and that MPV was initially low 
in our patients due to the likelihood of platelet activ-
ity being a secondary phenomenon for these very 
reasons. In order to verify this information, there is a 
need for prospective studies where serial measure-
ments of MPV and platelet counts are taken.
In one study, MPV elevation was found to be 
associated  with  poor  prognosis  independently  of 
concomitant factors.18 Although this phenomenon is 
well-known in coronary artery disease, there are not 
any adequate studies among patients with ischemic 
stroke. In our study we were unable to demonstrate 
a  relationship  between  modified  Rankin  scores 
measured on day 1 and day 10 and platelet count 
and  MPV.  The  view  that  platelet  activity  is  more 
marked in more severe strokes was not supported 
with these results. Nevertheless, we found no corre-
lation between prolactin levels and modified Rankin 
scores. Although prolactin increases the risk of isch-
emic stroke through platelet activation, further work 
is needed to reveal the relationship between this 
pathophysiological process and prognosis.
In summary, our study supports the hypothesis 
that ischemic stroke patients have higher levels of 
prolactin; however, prolactin is not correlated with 
early MPV measurements as a marker of platelet 
activation. If new clinical trials are conducted to in-
vestigate whether prolactin is a risk factor for isch-
emic stroke, how prolactin relates to prognosis and 
to what extent it contributes to platelet activation, 
this will reduce the existing question marks.
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